Clinical Study
Testing a New Drug called Venglustat Compared to the Standard of Care on the Heart in Adults with Fabry Disease (The CARAT (EFC16158) Study)
This study will test a new drug called Venglustat compared to the usual standard of care treatment in adults with Fabry Disease. This study is for people who have heart problems (enlargement of the heart's main pump (left ventricle)). Participants in this study will be randomized to be treated with Venglustat or one of the standard of care treatments. Later in the study, participants on the standard of care treatment can be switched to Venglustat. Participants will be in the study for 2 years and 2 months. There will be several clinic visits for the study and there may be the option for some home health visits. There will also be phone call visits.
For more information contact:
Carrie Bailey
carrie.bailey@hsc.utah.edu
8015873605
IRB#: IRB_00167895
| PI: Brian Shayota
| Department: PEDIATRIC GENETICS
| Approval Date: 2023-09-27 06:00:00
Specialties: Pediatric Genetics
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18 to 65 years old
- Confirmed diagnosis of Fabry disease
- Diagnosed left ventricular hypertrophy (enlargement and thickening of the heart's main pump (left ventricle))
- Willing to use specific birth control during study participation
- Attend in person at the study clinic with some options for home health visits
Exclusion Criteria:
- History of stroke, heart failure, heart surgery
- History of seizures requiring treatment
- Medical condition that may cause left ventricular hypertrophy
- Current severe depression measured by Becks Depression Inventory (BDI)
- History of drug or alcohol abuse
Will I be paid for my time?
Yes